Literature DB >> 27928191

Defibrotide.

Danial E Baker, Kendra Demaris.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433. The November 2016 monograph topics are apaziquone, crisaborole, irinotecan liposome, plecanatide, and telotristat. The Safety MUE is on methylnaltrexone PO.

Entities:  

Year:  2016        PMID： 27928191      PMCID： PMC5135434          DOI： 10.1310/hpj5110-847

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  31 in total

1.  SOS for veno-occlusive disease: defibrotide prophylaxis.

Authors:  Uwe Platzbecker; Martin Bornhäuser
Journal:  Lancet       Date:  2012-02-23       Impact factor: 79.321

2.  Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study.

Authors:  R Chopra; J D Eaton; A Grassi; M Potter; B Shaw; C Salat; P Neumeister; G Finazzi; M Iacobelli; K Bowyer; H G Prentice; T Barbui
Journal:  Br J Haematol       Date:  2000-12       Impact factor: 6.998

3.  Escalation to High-Dose Defibrotide in Patients with Hepatic Veno-Occlusive Disease.

Authors:  Brandon M Triplett; Hani I Kuttab; Guolian Kang; Wing Leung
Journal:  Biol Blood Marrow Transplant       Date:  2015-08-14       Impact factor: 5.742

4.  Drug-induced in vitro inhibition of neutrophil-endothelial cell adhesion.

Authors:  F Pellegatta; Y Lu; A Radaelli; M R Zocchi; E Ferrero; S Chierchia; G Gaja; M E Ferrero
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

Review 5.  Prophylaxis and treatment recommendations for sinusoidal obstruction syndrome in adult and pediatric patients undergoing hematopoietic stem cell transplant: a review of the literature.

Authors:  Sarah A Hopps; Emily B Borders; Tracy M Hagemann
Journal:  J Oncol Pharm Pract       Date:  2015-06-30       Impact factor: 1.809

6.  Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy.

Authors:  Ursula Haussmann; Joachim Fischer; Stefan Eber; Franziska Scherer; Reinhard Seger; Tayfun Gungor
Journal:  Haematologica       Date:  2006-06       Impact factor: 9.941

7.  Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children.

Authors:  Amrana Qureshi; Lynley Marshall; Donna Lancaster
Journal:  Pediatr Blood Cancer       Date:  2008-04       Impact factor: 3.167

8.  Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation.

Authors:  Yves Chalandon; Eddy Roosnek; Bernadette Mermillod; Anita Newton; Hulya Ozsahin; Pierre Wacker; Claudine Helg; Bernard Chapuis
Journal:  Biol Blood Marrow Transplant       Date:  2004-05       Impact factor: 5.742

9.  BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.

Authors:  Fiona L Dignan; Robert F Wynn; Nedim Hadzic; John Karani; Alberto Quaglia; Antonio Pagliuca; Paul Veys; Michael N Potter
Journal:  Br J Haematol       Date:  2013-09-17       Impact factor: 6.998

Review 10.  Hematopoietic stem cell transplant-associated thrombotic microangiopathy: review of pharmacologic treatment options.

Authors:  Sara S Kim; Monank Patel; Kendra Yum; Alla Keyzner
Journal:  Transfusion       Date:  2014-09-11       Impact factor: 3.157
View more
  3 in total

1.  Prophylactic Effect of Recombinant Human Soluble Thrombomodulin for Hepatic Sinusoidal Obstruction Syndrome Model Mice.

Authors:  Shunsuke Kanou; Tomoharu Miyashita; Yasuhiko Yamamoto; Satoshi Takada; Makoto Nakura; Mitsuyoshi Okazaki; Yoshinao Ohbatake; Shinichi Nakanuma; Isamu Makino; Hidehiro Tajima; Hiroyuki Takamura; Sachio Fushida; Tetsuo Ohta
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Fibrin clot characteristics and anticoagulant response in a SARS-CoV-2-infected endothelial model.

Authors:  Conor McCafferty; Leo Lee; Tengyi Cai; Slavica Praporski; Julian Stolper; Vasiliki Karlaftis; Chantal Attard; David Myint; Leeanne M Carey; David W Howells; Geoffrey A Donnan; Stephen Davis; Henry Ma; Sheila Crewther; Vinh A Nguyen; Suelyn Van Den Helm; Natasha Letunica; Ella Swaney; David Elliott; Kanta Subbarao; Vera Ignjatovic; Paul Monagle
Journal:  EJHaem       Date:  2022-03-22

Review 3.  Unresolved Issues in RNA Therapeutics in Vascular Diseases With a Focus on Aneurysm Disease.

Authors:  Isabel N Schellinger; Angelika R Dannert; Karin Mattern; Uwe Raaz; Philip S Tsao
Journal:  Front Cardiovasc Med       Date:  2021-04-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.